 |
| ABLYNX (D) |
|
|
|
|
| Codes and classification |
|
| ISIN |
BE0003877942 |
Mnemo |
ABLX |
CFI |
ESVUFB |
|
|
|
| Market |
EURONEXT BRUSSELS - Euronext - Local Securities |
| Type |
Stock - Ordinary stock - Continuous |
Compartment C (Small Caps) |
|
|
|
|
|
|
|
| ICB sectorial classification |
|
|
|
|
|
| Activity |
Ablynx is a biopharmaceutical company specializes in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases, including inflammation, thrombosis, oncology and pulmonary disease.
The company has over 25 projects in the pipeline and there are six Nanobodies in clinical development.
|
|
| Source: COFISEM - Last update: 18/11/11 |
|
|
|
|
|
| Key figures |
| Millenium |
2010 |
2009 |
2008 |
| Revenue* |
31,432 |
29,683 |
16,755 |
| Operating profit* |
-25,865 |
-22,160 |
-20,575 |
| Net profit |
-24,470 |
-19,995 |
-15,223 |
| Shareholder's equity |
100,790 |
76,126 |
93,870 |
| Total assets |
131,390 |
101,922 |
126,523 |
| Fiscal year end |
12.10 |
12.09 |
12.08 |
| Length of fiscal year (months) |
12 |
12 |
12 |
| Currency & Unit |
EUR - THOUSANDS |
EUR - THOUSANDS |
EUR - THOUSANDS |
| Account standards |
IFRS |
IFRS |
IFRS |
|
|
Source:
COFISEM -
Last update:
18/11/11 |
|
|
|
|
|
|
|
|
Ablynx
Technologiepark 21
9052 Zwijnaarde
Belgium
Phone number:+32 (0)9 262 00 00
Fax:+32 (0)9 262 00 01
http://www.ablynx.com
|
|
|
|
|
|
| Company contact |
Marieke Vermeersch
investors@ablynx.com
Phone number:00 32 9 262 00 00
|
|
Source:
ABLYNX (D)
- Last update: 30/03/11 |
|
|
|
|
|
|
|
| Top management |
| Chairman and Chief Executive Officer |
Edwin Moses |
| Chief Business Officer |
Eva-Lotta Allan |
| Chief Medical Officer |
Josefin-Beate Holz |
| Chief Financial Officer |
Wim Ottevaere |
| Investor Relations |
Marieke Vermeersch |
|
|
Source:
COFISEM
- Last update: 18/11/11 |
|
|
|
|
|
|
| Shareholders |
| Other shareholders |
29.0 % |
| GIMV |
18.32 % |
| Sofinnova Partners |
13.59 % |
| Abingworth Bioventures |
9.41 % |
| Alta California Partners IV |
7.19 % |
| Gilde Europe Food & Agribusiness Fund |
6.74 % |
| C.H. Boehringer Sohn |
4.91 % |
| Nederlandia Investments and Multifund |
4.36 % |
| KBC Private Equity |
3.24 % |
| VIB |
3.15 % |
|
|
Source:
COFISEM
- Last update: 18/11/11 |
|
|
|
|
|
|
|
|
|
|
| |
Some explanations on the accounts
Net profit:
The net (after tax) profit for the entire group as a whole.
This includes the Group's share of the net profit, as well as
the net profit for the minority interests.
IAS-IFRS standard
2005 accounts for companies listed on Eurolist are in
the IAS-IFRS accounting standard. Companies
listed on a regulated market are under the obligation to publish
their 2005 aggregated accounts in the IAS-IFRS standard.
Data in IAS-IFRS standard
In the « Bank » sector, the « Net sales » corresponds to « Revenues
» (or « Net sales »)
In the "Insurance" sector, the « Premiums» corresponds to the
« Revenues » (or « Net sales »).
In the "Listed property trusts" sector, the « Gross rental income»corresponds
to the « Revenues » (or « Net sales »).
In the "Société de Portefeuille" sector, the « Income» corresponds
to the « Revenues » (or « Net sales »).
Data in local standard
*Those data are based on the Accounting standards in force in
the "Industry" sector, excepted for some anglo-saxon listed
companies which use "Operating profit" instead of "Operating
income".
In the « Bank » sector, the « Net banking incomes » corresponds
to « Revenues » (or « Net sales »).
In the "Insurance" sector, the « Premiums» corresponds to the
« Revenues » (or « Net sales »).
In the other sectors with a specific activity, the « Investment
revenues» corresponds to the « Revenues » (or « Net sales »),
the « Operating income » to the « Operating profit ».
|
|
|
|
|
